Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-382, cFMS inhibitor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARRY-382 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-382, cFMS inhibitor; oral | DRUG | multiple dose, escalating |
Key Inclusion Criteria: * A histologically or cytologically confirmed diagnosis of advanced or metastatic solid cancer refractory to standard treatment, for which no standard therapy is available or for which the patient refuses standard therapy. * Measurable disease or evaluable, nonmeasurable dis...
Top 2 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ARRY-382 is an investigational oral small molecule being studied in patients with selected advanced or metastatic cancers. It was evaluated in a Phase 1 study in adults with metastatic cancer. It is not an approved therapy and remains in clinical development for oncology indications.
ARRY-382 targets CSF1R, also known as cFMS, the colony stimulating factor 1 receptor. It is a small molecule inhibitor of that receptor. Targeting CSF1R is intended to affect signaling pathways involved in the tumor microenvironment and macrophage biology in advanced or metastatic cancers.
ARRY-382 is being developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer holds the development program for this oral CSF1R inhibitor, which has been studied in patients with selected advanced or metastatic cancers.
ARRY-382 is in Phase 1 development. It is an investigational agent and has not been approved by the FDA. The single Phase 1 study of ARRY-382 has been completed, and no trials are currently listed as active.
ARRY-382 was studied in one Phase 1 trial, NCT01316822, titled A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers. That trial enrolled 26 patients in the United States, was uncontrolled, and has been completed. No active trials are listed.
Yes. ARRY-382 is also referred to as a cFMS inhibitor, and the oral formulation is described as ARRY-382, cFMS inhibitor; oral. cFMS is another name for CSF1R, the molecular target of this small molecule. These names refer to the same investigational compound developed by Pfizer.